Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Age De-escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Late Liver Stage-arresting, Replication-competent Plasmodium Falciparum Sporozoite Vaccine (Sanaria® PfSPZ-LARC2 Vaccine) Administered by Direct Venous Inoculation to Malaria-exposed Adults and Children in Burkina Faso

NCT06652737 is registered in ClinicalTrials.gov with Sanaria Inc. as lead sponsor.

NCT NCT06652737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06652737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Age De-escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Late Liver Stage-arresting, Replication-competent Plasmodium Falciparum Sporozoite Vaccine (Sanaria® PfSPZ-LARC2 Vaccine) Administered by Direct Venous Inoculation to Malaria-exposed Adults and Children in Burkina Faso
Lead sponsor
Sanaria Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 4, 2025
Completion date
February 18, 2026
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria falciparum, malaria infection